Immupharma (IMM)

 

Latest News

Grant of Options

RNS Number: 4907X Immupharma PLC 24 November 2017 24 NOVEMBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Grant of Options ImmuPharma PLC (LSE:IMM) , ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 7,875,000 ordinar...

Lupuzor trial on track, says ImmuPharma

ImmuPharma is on track to report top line results from its 52-week, randomised, double-blinded, phase III clinical trial of ...

Update on LupuzorT Pivotal Phase III Study

RNS Number: 3263V Immupharma PLC 02 November 2017 2 November 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinic...

Holding(s) in Company

RNS Number: 7306T Immupharma PLC 16 October 2017 TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma Plc 213800VZKGHXC7VUS895 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK iss...

All News

DateHeadlineSource
11-02-15Immupharma completes clinical trial StockMarketWire
11-02-15CANCER UPDATE: IPP-204106RNS
27-01-15ImmuPharma gets assurance over EIS StockMarketWire
27-01-15Enterprise Investment Scheme StatusRNS
22-01-15FTSE surges as ECB unveils QE, financials riseStockMarketWire
22-01-15FTSE cautiously up as ECB's QE call nearsStockMarketWire
22-01-15Collaboration Agreement with Simbec-OrionRNS
30-10-14Holding(s) in CompanyRNS
28-10-14Holding(s) in CompanyRNS
21-10-14FTSE 100 makes strong recoveryStockMarketWire
21-10-14FTSE 100 bounces backStockMarketWire
21-10-14ImmuPharma raises £3.4m StockMarketWire
21-10-14Additional Listing - Conditional PlacingRNS
20-10-14ImmuPharma unit awarded €400,000 grant StockMarketWire
20-10-14ImmuPharma awarded EUR400,000 GrantRNS
30-09-14Losses remain at ImmuPharmaStockMarketWire
30-09-14Half Yearly ReportRNS
30-09-14LupuzorT Gears Up To Start Pivotal Phase III trialRNS
27-06-14Immupharma shareholders approve AGM resolutionsStockMarketWire
27-06-14Result of AGMRNS
27-06-14ImmuPharma extends research capabilitiesStockMarketWire
27-06-14Access to pioneering research in Bordeaux FranceRNS
16-06-14ImmuPharma granted new Nucant patents StockMarketWire
16-06-14NEW NUCANT PATENTSRNS
23-05-14Annual Financial ReportRNS
21-05-14ImmuPharma pre-tax losses riseStockMarketWire
21-05-14Preliminary ResultsRNS
06-05-14ImmuPharma gives summary from lupus conference StockMarketWire
06-05-14Dr. Sylviane Muller - Presentation AbstractRNS
23-04-14Lupuzor founder presents at Osaka UniversityStockMarketWire
23-04-14Dr. S Muller, founder of Lupuzor presentation.RNS
11-04-14ImmuPharma Sponsors the 2014 European Lupus ConferRNS
14-10-13Additional ListingRNS
27-09-13ImmuPharma trims operating lossStockMarketWire
27-09-13Half Yearly ReportRNS
13-08-13ImmuPharma gives update on cancer programmeStockMarketWire
13-08-13UPDATE CANCER PROGRAMME IPP-204106RNS
31-07-13FDA GRANTS IMMUPHARMA AMENDED SPARNS
08-07-13ImmuPharma appoints opinion leaders to advisory board StockMarketWire
08-07-13ImmuPharma appoints opinion leaders to advisory board StockMarketWire

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account